These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9179216

  • 1. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
    Kastelan M, Kovacić K, Tarle R, Kraljić I, Tarle M.
    Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
    [Abstract] [Full Text] [Related]

  • 2. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M, Kovacić K, Kastelan M.
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [Abstract] [Full Text] [Related]

  • 3. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M, Kraljić I.
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [Abstract] [Full Text] [Related]

  • 4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M.
    Anticancer Res; 1993 Feb; 13(3):769-77. PubMed ID: 7686362
    [Abstract] [Full Text] [Related]

  • 6. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K.
    Prostate; 2005 Jan 01; 62(1):34-9. PubMed ID: 15389818
    [Abstract] [Full Text] [Related]

  • 8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 15; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 10. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun 15; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

  • 11. Cytokeratin markers in patients with prostatic diseases.
    Wolff JM, Borchers H, Brehmer B, Brauers A, Jakse G.
    Anticancer Res; 1999 Jun 15; 19(4A):2649-52. PubMed ID: 10470212
    [Abstract] [Full Text] [Related]

  • 12. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB, Robson CN, Neal DE, Leung HY.
    J Urol; 2000 Dec 15; 164(6):2151-5. PubMed ID: 11061946
    [Abstract] [Full Text] [Related]

  • 13. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D, Galosi AB, Dell'Atti L, Hanitzsch H, Mario P, Muzzonigro G.
    Scand J Urol Nephrol; 2002 Dec 15; 36(5):323-9. PubMed ID: 12487735
    [Abstract] [Full Text] [Related]

  • 14. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Dec 15; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 15. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
    Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC.
    Cancer Res; 1992 Jun 15; 52(12):3323-8. PubMed ID: 1375867
    [Abstract] [Full Text] [Related]

  • 16. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
    Zenimoto M, Kita M, Arai T, Murayama T, Mori M.
    Rinsho Byori; 2003 Oct 15; 51(10):969-73. PubMed ID: 14653195
    [Abstract] [Full Text] [Related]

  • 17. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M, Kovacic K, Kraljic I, Tarle M.
    Anticancer Res; 2001 Oct 15; 21(2B):1475-9. PubMed ID: 11396235
    [Abstract] [Full Text] [Related]

  • 18. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP, Bi XJ, Li YN, Chen XQ, Zhang XF, Yu XP, Liu G, Yang MC, Song Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan 15; 27(1):107-8, 112. PubMed ID: 17259162
    [Abstract] [Full Text] [Related]

  • 19. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E.
    J Urol; 1998 May 15; 159(5):1599-605. PubMed ID: 9554362
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.